# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: George H. W. Bush (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML018-SYN
- Date: 2026-05-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Douglas Whitford, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review on methimazole for Graves' disease and atrial fibrillation. **S**

## History of present illness

Mr. Bush returns twelve days after starting methimazole 20 mg daily, on metoprolol succinate 50 mg daily and apixaban 5 mg twice daily since his hospital stay. He has had no palpitations or irregular pulse on his home monitor and feels well. He has walked daily but has not run yet, as advised. He has had no fever, sore throat, mouth ulcers, rash, itching, yellow eyes, or dark urine on methimazole, and no bleeding or bruising on apixaban. He takes every dose. He has no eye pain, grittiness, or double vision. He saw the endocrinologist this morning, and radioactive iodine is planned for next week. **S**

| Element | Detail |
|---|---|
| Rhythm | No palpitations; regular pulse on home checks |
| Thyrotoxic symptoms | Feels well; still a little heat-intolerant |
| Methimazole safety | No fever, sore throat, rash, jaundice, or dark urine |
| Apixaban safety | No bleeding or bruising; no missed doses |
| Activity | Daily walks; not yet running |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No palpitations, chest pain, lightheadedness, or ankle swelling |
| Constitutional | Positive | Still a little heat-intolerant; no fever |
| Eyes | Negative | No grittiness, pain, redness, or double vision |
| Hematologic | Negative | No bleeding or bruising |

4 systems reviewed. **S**

## Current medications

- Metoprolol succinate extended-release 50 mg oral tablet, one tablet by mouth daily (started in hospital) **S**
- Apixaban 5 mg oral tablet, one tablet by mouth twice daily (started in hospital) **S**
- Methimazole 10 mg oral tablet, two tablets (20 mg) by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 132/70 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.9 °C; oxygen saturation 98% on room air; weight 86.4 kg; BMI 24.4 kg/m². All vital signs are synthetic.

TSH: 0.01 mIU/L (low); Free T4: 2.2 ng/dL (high); Total T3: 176 ng/dL; Absolute neutrophil count: 3.5 10*3/uL; ALT: 30 U/L. All results are synthetic.

## Change since baseline

- TSH: 0.005 mIU/L (low) at baseline, 0.01 mIU/L (low) at this visit **S**
- Free T4: 3.6 ng/dL (high) at baseline, 2.2 ng/dL (high) at this visit **S**
- Total T3: 280 ng/dL (high) at baseline, 176 ng/dL at this visit **S**
- Absolute neutrophil count: 3.9 10*3/uL at baseline, 3.5 10*3/uL at this visit **S**
- ALT: 32 U/L at baseline, 30 U/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; calmer than at intake |
| Eyes | No lid retraction, lid lag, proptosis, or redness; eye movements full |
| Neck | Diffusely enlarged, non-tender thyroid without nodules |
| Cardiovascular | Regular rhythm at 72 per minute; no murmur |
| Neurological | Fine tremor of the outstretched hands, less than at intake |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Graves' disease with hyperthyroidism, improving on methimazole** (E05.00). Free T4 2.2 ng/dL, down from 3.6, and total T3 176 ng/dL, now in range; TSH still suppressed at 0.01, as expected. Neutrophil count 3.5 x10³/µL and ALT 30 U/L are normal on methimazole. The endocrinologist confirms Graves' disease without eye disease and recommends radioactive iodine. **S**
   - Stop methimazole three days before radioactive iodine, which is booked for next week.
   - Radiation-safety instructions given in writing by the endocrinology clinic.
   - Free T4 and total T3 six to seven weeks after the treatment.
   - Expect hypothyroidism within weeks to months; levothyroxine when it comes.
2. **Paroxysmal atrial fibrillation, in sinus rhythm** (I48.0). Sinus rhythm at 72 per minute on metoprolol, with no recurrence since discharge. CHA2DS2-VASc 1 and HAS-BLED 1; apixaban continues while he is thyrotoxic, as agreed at intake. **S**
   - Continue metoprolol succinate 50 mg daily and apixaban 5 mg twice daily.
   - Gentle running can resume in two weeks if his pulse stays regular.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Heart rate and rhythm | Every visit | Completed today | 72 per minute, regular; no recurrence of atrial fibrillation since discharge |
| Examination | Blood pressure | Every visit; target below 130/80 | Completed today | 132/70 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 86.4 kg, BMI 24.4 |
| Survey | Atrial fibrillation symptoms | Every visit | Completed today | None |
| Imaging | 12-lead ECG or rhythm strip | When rhythm assessment is indicated or symptoms change | Not indicated | Pulse regular on examination and on home checks; intake ECG in sinus rhythm |
| Imaging | Transthoracic echocardiogram | At diagnosis; repeat with clinical change | Up to date | Normal structure, left atrial size, and ejection fraction in hospital |
| Survey | CHA2DS2-VASc and HAS-BLED | Yearly and with any change in clinical status | Up to date | Scored at intake: CHA2DS2-VASc 1 (age 65 to 74), HAS-BLED 1 (age over 65) |
| Medication safety | Anticoagulant adherence and bleeding | Every visit | Completed today | No missed doses; no bleeding |
| Laboratory | Creatinine and eGFR on apixaban | At baseline and at least yearly | Up to date | Creatinine 0.92 mg/dL, eGFR 87 at intake; full dose is correct |
| Laboratory | Hemoglobin on anticoagulation | At least yearly; sooner with symptoms | Up to date | 14.8 g/dL at intake |
| Self-management | Alcohol, tobacco, and physical activity | Every visit | Completed today | No alcohol since the hospital stay; never used tobacco; daily walks, running to resume in steps |
| Survey | Sleep apnea symptom screen | At diagnosis and at least yearly | Deferred | Not asked at intake or today. Deviation: the screen due at diagnosis was missed; it is added to the next visit's checklist |
| Laboratory | Free T4 and total T3 on methimazole | Two to six weeks after starting, then every four to eight weeks | Completed today | Free T4 2.2 ng/dL, total T3 176 ng/dL, TSH 0.01 mIU/L |
| Laboratory | White cell count with differential and liver tests on methimazole | At baseline; then with fever, sore throat, jaundice, or other symptoms | Completed today | Checked before radioactive iodine at the consultant's request: neutrophils 3.5 x10³/µL, ALT 30 U/L |
| Medication safety | Methimazole side effects | Every visit while on methimazole | Completed today | None; written warning about fever and sore throat repeated |
| Examination | Eye assessment for Graves' orbitopathy | At diagnosis and before radioactive iodine | Completed today | No orbitopathy; never smoker, so no steroid cover is needed |
| Referral | Endocrinology consultation | At diagnosis of Graves' disease, to choose definitive treatment | Completed today | Seen today; radioactive iodine chosen |

## Goal progress

- Resting heart rate below 110 per minute without palpitations while thyrotoxic. Outcome by 2026-05-20: Heart rate 72 in sinus rhythm on metoprolol two weeks after intake. **S**
- No atrial fibrillation once no longer thyrotoxic, confirmed by ambulatory monitoring before the anticoagulation decision. In progress; target 2026-09-11. **S**
- TSH within 0.4 to 4.0 mIU/L on levothyroxine. In progress; target 2026-10-16. **S**
- Back to running three miles several days a week without symptoms. In progress; target 2026-09-11. **S**

## Guideline basis

- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation (2023), American College of Cardiology, American Heart Association, American College of Chest Physicians, and Heart Rhythm Society (Circulation 2024;149(1):e1-e156)
- 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016), American Thyroid Association (Thyroid 2016;26(10):1343-1421)
- CMID: Clinical Monitoring Intelligence Database, atrial fibrillation and hypothyroidism monographs (2026), Aether Forge

## Follow-up

- Radioactive iodine next week. Review with thyroid tests in about seven weeks, or sooner for palpitations, fever, or sore throat. **S**
- Next scheduled visit 2026-07-17: seven-week review after radioactive iodine. **S**
